Dr. Søren Weis Dahl, MBA, Chief Executive Officer
Dr. Dahl came to Prophylix in 2012 as Coordinator for the EU-funded PROFNAIT project and took on the role as Chief Business Officer a year later before being appointed Chief Executive in April 2015. Dr. Dahl has held leadership positions in biotech, pharma and diagnostics companies before joining Prophylix and for four years he worked as a biotech management consultant with focus on market research, business and strategy development and valuation.
Dr. Jens Kjeldsen-Kragh, MD, Chief Scientific Officer
Dr. Kjeldsen-Kragh is one of the founders of Prophylix. His has postgraduate training as specialist in Clinical Immunology and Transfusion Medicine and has worked within this field for more than 25 years. He has previously hold positions as Senior Consultant Physician at the Blood Bank in Oslo and as Professor at the University of Oslo, Norway. Dr. Kjeldsen-Kragh is currently working as Chief Scientific Officer in Prophylix (50 %) and Senior Consultant Physician at University and Regional Laboratories Region Skåne, Sweden (50 %). He has extensive clinical and scientific experience within the field of platelet immunobiology.
Dr. Torgeir Vaage, Chief Financial Officer
Dr. Vaage serves as the Chief Financial Officer at Prophylix Pharma AS and at SantoSolve AS and brings extensive experience from the financial industry in Norway. Prior to joining Prophylix, Dr. Vaage served as a Financial Analyst with several Scandinavian investment banks, including ABG Sundal Collier Holding ASA, Research Division, Handelsbanken Capital Markets, Research Division, and Norden Equity. He holds an M.Sc. from Norges Handelshøyskole, Norway and a Ph.D. from UC Berkeley.
Dr. Mette Kjær, Chief Operating Officer
Mette holds a Post Doc position at University Hospital of North Norway and is Chief Operating Officer (COO) at Prophylix Pharma AS. She is one of the Founders of the company and has been working with FNAIT research for more than 10 years. Dr. Kjær received her Ph.D. in immunology from the University of Tromsø in 2008 and was engaged at St. Michaels Hospital, Toronto, Canada, in research on prophylactic treatment of FNAIT in an animal model.